Stevens Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Stevens Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-124	Closed	-$380K	–	1200
2016 Q2	$380K	Sell	124 -1	-0.8%	-$3.25K	0.02%	635
2016 Q1	$397K	Buy	+125	New	+$519K	0.02%	620
2015 Q2	–	Sell	-94	Closed	-$374K	–	1298
2015 Q1	$374K	Buy	+94	New	+$431K	0.01%	665
2014 Q1	–	Sell	-173	Closed	-$608K	–	1381
2013 Q4	$608K	Sell	173 -30	-15%	-$117K	0.02%	592
2013 Q3	$834K	Buy	203 +4	+2%	+$17.2K	0.02%	523
2013 Q2	$786K	Buy	+199	New	+$819K	0.03%	479

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Stevens Capital Management's ACOR Position: Q3 2016 in Review

Stevens Capital Management sold out of Acorda Therapeutics (ACOR) in Q3 2016, closing a stake of 124 shares — an estimated $380K sold.

Stevens Capital Management first reported a position in ACOR in Q2 2013 and held it in 6 quarters. The position peaked at $834K in Q3 2013. 167 funds tracked by Wall St. Rank hold ACOR as of Q3 2016.

Stevens Capital Management reported no remaining Acorda Therapeutics position as of Q3 2016 after selling out during the quarter.
Stevens Capital Management sold 124 Acorda Therapeutics shares in Q3 2016, an estimated $380K.
Stevens Capital Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 6 quarters.
Stevens Capital Management's Acorda Therapeutics position peaked at $834K in Q3 2013.
167 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2016.

Based on Stevens Capital Management's 13F filing for Q3 2016, filed 8 Nov 2016.